開示情報 > Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headache

Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headache

Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headache

開示者 【45650】ネクセラファーマ株式会社
文書名 Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headache  
PDF/XBRL [別ウインドウでPDFを開く]
開示日時 2018/03/13 チャネル/カテゴリ 東京証券取引所 /その他
ノート ログインするとIR文書にメモを入力して管理することができます
右上のログインメニューからログインしてください。


開示情報 > Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headache